Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene Eyes $6.1M in Public Offering

NEW YORK (GenomeWeb News) – Trovagene said in a regulatory filing on Wednesday that it is publicly offering $6.1 million of its common stock.

In total, the company plans on offering more than 1.2 million shares, which will be issued upon the exercise of outstanding warrants that Trovagene issued in mid-2012 as part of a public offering when the company moved to the Nasdaq.

The common stock offering is part of a $150 million shelf registration that the company filed with SEC earlier this week.

The San Diego-based molecular diagnostics firm will offer up to 1.15 million shares of its stock at $5.32 per share from time to time upon the exercise of the currently outstanding warrants, it said in a document filed with the US Securities and Exchange Commission. It also will issue up to 92,000 shares at $7 per share from time to time upon exercise of the outstanding warrants issued to the underwriter and its designees.

The $6.1 million in net proceeds expected from the offering will go toward R&D, working capital, and general corporate purposes. Trovagene said it expects to have about 16.8 million shares of its common stock outstanding if all the warrants in the offering are exercised.

Shares of Trovagene were down 6 percent at $6.46 in afternoon trading.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.